In the recent study by Kotsopoulous et al., at 10 years of follow-up, 43% of non-carriers, 57% of BRCA1 mutation carriers, and 69% of BRCA2 mutation carriers died from ovarian cancer, being no residual disease at resection the strongest predictor of long-term survival [15]. The gene discussed is BRCA2; the disease is ovarian carcinoma.